Cytokinetics

Cardiovascular Account Specialist - U.S. Sales, Nashville, TN

Remote

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, Medical DevicesIndustries

Requirements

Candidates must possess a Bachelor’s degree and a minimum of 5 years of experience in biotech or pharmaceutical sales, with a preference for experience in cardiology, rare diseases, or specialty products. Launch experience with sole territory ownership is highly desirable.

Responsibilities

As a Cardiovascular Account Specialist, you will introduce Cytokinetics within your territory, launch its first commercial product for Hypertrophic Cardiomyopathy (HCM), and develop territory-specific account plans to identify and prioritize opportunities to meet customer needs. You will be responsible for building strategic relationships with IDNs, hospitals, cardiology clinics, and specialty pharmacies, serving as a subject matter expert, and communicating approved resources to healthcare professionals to support patients.

Skills

Sales
Account Management
Relationship Development
Healthcare Knowledge
Customer Engagement
Product Knowledge
Demand Generation

Cytokinetics

Develops drugs for muscle function disorders

About Cytokinetics

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, tailored to specific therapeutic needs. The company has a pipeline of drugs, including omecamtiv mecarbil and reldesemtiv, which are in various stages of clinical trials. Unlike many competitors, Cytokinetics emphasizes rigorous scientific research and has conducted over 50 clinical trials to ensure the effectiveness of its treatments. The goal is to bring new therapies to market that address the unmet needs of patients suffering from conditions like heart failure, ALS, and HCM.

Key Metrics

South San Francisco, CaliforniaHeadquarters
1998Year Founded
$58.4MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees

Risks

Increased competition could impact market share and profitability.
Potential delays in clinical trials could hinder drug commercialization.
Dependence on strategic partnerships may expose Cytokinetics to risks if challenges arise.

Differentiation

Cytokinetics focuses on muscle activators and inhibitors for cardiovascular and neuromuscular diseases.
The company has a robust pipeline including omecamtiv mecarbil and aficamten.
Cytokinetics engages in strategic partnerships, like with Sanofi, to expand market reach.

Upsides

Recent investments indicate strong interest in muscle activators and inhibitors.
Strategic partnerships, like with Sanofi, expand market reach and potential revenue.
Significant funding from Royalty Pharma supports commercial launch and R&D advancements.

Land your dream remote job 3x faster with AI